Competing pursuits
A.B.E.-Okay. has obtained cost or honoraria from and has served in a consulting or advisory function for Agenus. Inc., AstraZeneca/MedImmune, Bayer, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Gilead Sciences, Merck, QED Therapeutics, Qurient, Roche/Genentech, Senti Biosciences, Servier Laboratories and Tallac Therapeutics and obtained analysis funding from Astex Prescribed drugs, AstraZeneca and Fulgent Genetics. N.H.S. has obtained consulting charges from ABL Bio, Agenus, Inc., AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Numab, Puretech, Revitope and Roche/Genentech; assist for attending conferences and/or journey from AstraZeneca and Regeneron; and analysis funding from Agenus, Inc., AstraZeneca, Bristol Myers Squibb, Immunocore, Merck, Pfizer, Puretech, Regeneron and Roche/Genentech. B.B. has obtained analysis funding from Agenus, Inc. and NanoView Biosciences; obtained consulting charges from BioLineRx; obtained assist for attending conferences and/or journey from Agenus, Inc. and Erytech Pharma; and has participated in a knowledge security monitoring board or advisory board for Blueprint Medicines and Enlivex Therapeutics. B.A.W. has served in a consulting or advisory function for Aadi Bioscience, Adcendo, Boehringer Ingelheim, Deciphera, Epizyme, Polaris and SpringWorks; obtained analysis funding from Exelixis; and obtained journey, lodging or bills assist from Agenus, Inc. A.J.B. has obtained analysis funding from Agenus, Inc., AstraZeneca, Geistlich Pharma, Oncomatryx Biopharma and Panavance Therapeutics; obtained journey assist from Agenus, Inc.; and obtained consulting or advisory charges from Exelixis, Merck and Oncolytics. G.Okay.A.-A. has obtained grants or contracts from Agenus, Inc., Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Genentech/Roche, Helsinn, the Parker Institute for Most cancers Immunotherapy, Pertzye, Puma Biotechnology, QED Therapeutics and Yiviva; obtained consulting charges from Astellas, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, FibrioGen, Genentech/Roche, Incyte, Ipsen, Merck, Merus, Neogene Therapeutics, Novartis, Servier Prescribed drugs, Tempus, Thetis Prescribed drugs, Vector Pharma and Yiviva; and obtained assist for attending conferences and/or journey from Astellas, AstraZeneca, Autem, Berry Genomics, BioNTech, Bristol Myers Squibb, Boehringer Ingelheim, Eisai, Exelixis, Fibriogen, Genentech/Roche, Incyte, Ipsen, Merck, Merus, Neogene, Novartis, Servier, Tempus, Thetis, Vector and Yiviva. M.G.F. has obtained consulting charges from AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Mirati, Pfizer and Taiho and took part in a knowledge security monitoring or advisory board for Bayer, Eisai, Entos, Janssen, Merck, Mirati Therapeutics, Nouscom, Seattle Genetics and Xenthera. D.M. has obtained cost or honoraria for lectures, shows, speaker’s bureaus, manuscript writing or instructional occasions from Guardant Well being. J.C.M. has obtained analysis funding from Agenus, Inc.; obtained grants or contracts from Agenus, Inc., Alpine Immune Sciences, Amgen, BioEclipse Therapeutics, Destiny Therapeutics, FujiFilm, Genentech, Ideaya Biosciences, ImmuneSensor Therapeutics, Iovance, Istari Oncology, Nektar Therapeutics, NovoCure, Repertoire Immune Medicines, Rubius, Senwha, Simcha, Storm Therapeutics, Synthorx, T-Scan, Trishula Therapeutics, the College of Arizona, Werewolf Therapeutics and Y-mAbs Therapeutics; obtained consulting charges from Adagene, Amunix Prescribed drugs, Bristol Myers Squibb, Boxer Capital, Genome Perception, Incyte, Imaging Endpoints, IQVIA, Oberland Capital, Novotech CRO, Pink Arrow Therapeutics and Thirona Bio; served in a management or fiduciary function for Caris Life Sciences; and obtained cost or honoraria for lectures, shows, speaker’s bureaus, manuscript writing or instructional occasions from Caris Life Sciences, Daiichi Sankyo and TGen. S.S. has obtained cost or honoraria from Array BioPharma; served in a consulting or advisory function for Barricade Therapeutics, Celularity, Dracen Prescribed drugs and Elevar Therapeutics; obtained analysis funding from Aadi Bioscience, Amal Therapeutics, Celgene, Dracen Prescribed drugs, HonorHealth, Inhibrx, Merck, Nektar Therapuetics, Novartis, Plexxikon, Sirnaomics, Syndax Prescribed drugs, Takeda, Tesaro, Toray Industries and Zai Lab; and holds inventory and different possession pursuits with Barricade Therapeutics, Beta Cat Prescribed drugs, ConverGene, Elevar Therapeutics, HLB, Salarius Prescribed drugs and Stingray Therapeutics. R.E.S. has obtained analysis funding from AstraZeneca and Merck; obtained consulting charges from Amgen, AstraZeneca, Daiichi Sankyo, GE HealthCare, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Janssen, Regeneron and Sanofi Aventis; and obtained cost or honoraria for lectures, shows, speaker’s bureaus, manuscript writing or instructional occasions from the Binay Basis, EMD Serono, GameOn!, Illumina, OncLive and Focused Oncology. J.S. has obtained consulting charges from Agenus, Inc.; served on advisory boards for Alveo Applied sciences, APIM Therapeutics, Benevolent AI, Bryologyx, Celltrion, Certis, Scientific ink, Eli Lilly, Equilibre Biopharmaceuticals, Graviton Bioscience Company, Greenmantle, Warmth Biologics, IO Labs, Onconox, Pear Bio, Vaccitech, Volvox, vTv Therapeutics and Zephyr AI; and obtained cost or honoraria for lectures, shows, speaker’s bureaus, manuscript writing or instructional occasions from Celltrion and Eli Lilly. Since 2024, J.S. is on the board of administrators for Graviton Biosciences BV, Etira Therapeutics and Portage and has served in a management or fiduciary function for BB Healthcare Belief PLC and Xerion Healthcare. A.M.T. declares receipt of medical trial analysis funding (to The College of Texas MD Anderson Most cancers Heart) from Agenus, Inc., Immatics, Novocure, OBI Pharma, the Parker Institute for Most cancers Immunotherapy, Tachyon, Tempus and Tvardi; charges for consulting or advisory roles from Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, MacroGenics, NEX-I and VinceRx; and journey bills from the American Society of Scientific Oncology, Most cancers Care Crossroads, GenomeWeb Convention and Precision Medication World Convention. M.S.G. has served in a consulting or advisory function for Cardinal Healthcare, Imaging Endpoints, IQVIA, Medtronics, Onquality, Pfizer, Qualigen, Springworks Tx and Viracta; is co-owner of Sphinx Well being Options; and obtained institutional analysis assist from Agenus, Inc., BeiGene, DynamiCure, Fore, Genentech, NiKang, Novartis, Nimbus, OncoResponse, Plexxicon, Pyxis Oncology, Redhill Bio, Riboscience, Roche, SQZ Biotech, Syndax and Veru. G.Okay.S. has served in a consulting or advisory function for Aadi Subsidiary, Astex, Boehringer Ingelheim, Concarlo Therapeutics, Epizyme, Ipsen, Kirilys Therapeutics, OnCusp, Puretech Well being, Sellas Life Sciences and Shanghai Pharma and holds inventory in Bionaut and GenCirq. H.-J.L. has obtained consulting charges from Janssen and Pfizer and obtained cost or honoraria for lectures, shows, speaker’s bureaus, manuscript writing or instructional occasions from AstraZeneca, Bristol Myers Squibb, Genentech, Merck, Mirati and Regeneron. S.J.O., J.E.G., J.M.P., W.W., D.C., G.M., C.D. and Okay.R. are present or former workers of Agenus, Inc. and will maintain inventory/inventory choices. T.J.C. is a advisor for Agenus, Inc., Gmelich Chair, and has obtained funding from Guyre funds. The opposite authors declare no competing pursuits (A.P., A.S.B. and B.L.S.).
